1
|
Qin D, Lin X, Liu Z, Chen Y, Zhang Z, Wu C, Liu L, Pan Y, Laquerre S, Emery J, Fergusson J, Roland K, Keenan R, Oliff A, Kumar S, Cheung M, Su DS. Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors. ACS Med Chem Lett 2021; 12:1005-1010. [PMID: 34141085 DOI: 10.1021/acsmedchemlett.1c00160] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Accepted: 05/11/2021] [Indexed: 12/12/2022] Open
Abstract
We report herein the discovery of quinazolindiones as potent and selective tankyrase inhibitors. Elucidation of the structure-activity relationship of the lead compound 1g led to truncated analogues that have good potency in cells, pharmacokinetic (PK) properties, and excellent selectivity. Compound 21 exhibited excellent potencies in cells and proliferation studies, good selectivity, in vitro activities, and an excellent PK profile. Compound 21 also inhibited H292 xenograft tumor growth in nude mice. The synthesis, biological, pharmacokinetic, in vivo efficacy studies, and safety profiles of compounds are presented.
Collapse
Affiliation(s)
| | - Xiaojuan Lin
- WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Zhi Liu
- WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Yan Chen
- WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Zhiliu Zhang
- WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Chengde Wu
- WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Linlin Liu
- WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Yan Pan
- WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Huang JS, Guo BB, Lin FF, Zeng LM, Wang T, Dang XY, Yang Y, Hu YH, Liu J, Wang HY. A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism. Eur J Pharm Sci 2020; 158:105683. [PMID: 33347980 DOI: 10.1016/j.ejps.2020.105683] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2020] [Revised: 12/11/2020] [Accepted: 12/15/2020] [Indexed: 01/27/2023]
Abstract
Diacylglycerol acyltransferase 1 (DGAT1) plays a pivotal role in lipid metabolism by catalyzing the committed step in triglyceride (TG) synthesis and has been considered as a potential therapeutic target of multiple metabolic diseases, including dyslipidemia, obesity and type 2 diabetes. Here we report a novel DGAT1 inhibitor, Yhhu2407, which showed a stronger DGAT1 inhibitory activity (IC50 = 18.24 ± 4.72 nM) than LCQ908 (IC50 = 78.24 ± 8.16 nM) in an enzymatic assay and led to a significant reduction in plasma TG after an acute lipid challenge in mice. Pharmacokinetic studies illustrated that Yhhu2407 displayed a low systemic, liver- and intestine-targeted distribution pattern, which is consistent with the preferential tissue expression pattern of DGAT1 and therefore might help to maximize the beneficial pharmacological effects and prevent the occurrence of side effects. Cell-based investigations demonstrated that Yhhu2407 inhibited free fatty acid (FFA)-induced TG accumulation and apolipoprotein B (ApoB)-100 secretion in HepG2 cells. In vivo study also disclosed that Yhhu2407 exerted a beneficial effect on regulating plasma TG and lipoprotein levels in rats, and effectively ameliorated high-fat diet (HFD)-induced dyslipidemia in hamsters. In conclusion, we identified Yhhu2407 as a novel DGAT1 inhibitor with potent efficacy on improving lipid metabolism in rats and HFD-fed hamsters without causing obvious adverse effects.
Collapse
Affiliation(s)
- Jun-Shang Huang
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China
| | - Bin-Bin Guo
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Fei-Fei Lin
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Li-Min Zeng
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Ting Wang
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Xiang-Yu Dang
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Yang Yang
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China
| | - You-Hong Hu
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.
| | - Jia Liu
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
| | - He-Yao Wang
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.
| |
Collapse
|
3
|
Accelerating the discovery of DGAT1 inhibitors through the application of parallel medicinal chemistry (PMC). Bioorg Med Chem Lett 2019; 29:1380-1385. [DOI: 10.1016/j.bmcl.2019.03.039] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Revised: 03/19/2019] [Accepted: 03/25/2019] [Indexed: 11/20/2022]
|
4
|
Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moiety. Bioorg Med Chem Lett 2019; 29:1182-1186. [DOI: 10.1016/j.bmcl.2019.03.025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2018] [Revised: 03/09/2019] [Accepted: 03/20/2019] [Indexed: 02/05/2023]
|
5
|
Mitra R, Le TT, Gorjala P, Goodman OB. Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5. BMC Cancer 2017; 17:631. [PMID: 28877685 PMCID: PMC5588693 DOI: 10.1186/s12885-017-3589-6] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2017] [Accepted: 08/22/2017] [Indexed: 12/30/2022] Open
Abstract
Background Neoplastic cells proliferate rapidly and obtain requisite building blocks by reprogramming metabolic pathways that favor growth. Previously, we observed that prostate cancer cells uptake and store lipids in the form of lipid droplets, providing building blocks for membrane synthesis, to facilitate proliferation and growth. Mechanisms of lipid uptake, lipid droplet dynamics and their contribution to cancer growth have yet to be defined. This work is focused on elucidating the prostate cancer-specific modifications in lipid storage pathways so that these modified gene products can be identified and therapeutically targeted. Methods To identify genes that promote lipid droplet formation and storage, the expression profiles of candidate genes were assessed and compared between peripheral blood mononuclear cells and prostate cancer cells. Subsequently, differentially expressed genes were inhibited and growth assays performed to elucidate their role in the growth of the cancer cells. Cell cycle, apoptosis and autophagy assays were performed to ascertain the mechanism of growth inhibition. Results Our results indicate that DGAT1, ABHD5, ACAT1 and ATGL are overexpressed in prostate cancer cells compared to PBMCs and of these overexpressed genes, DGAT1 and ABHD5 aid in the growth of the prostate cancer cells. Blocking the expression of both DGAT1 and ABHD5 results in inhibition of growth, cell cycle block and cell death. DGAT1 siRNA treatment inhibits lipid droplet formation and leads to autophagy where as ABHD5 siRNA treatment promotes accumulation of lipid droplets and leads to apoptosis. Both the siRNA treatments reduce AMPK phosphorylation, a key regulator of lipid metabolism. While DGAT1 siRNA reduces phosphorylation of ACC, the rate limiting enzyme in de novo fat synthesis and triggers phosphorylation of raptor and ULK-1 inducing autophagy and cell death, ABHD5 siRNA decreases P70S6 phosphorylation, leading to PARP cleavage, apoptosis and cell death. Interestingly, DGAT-1 is involved in the synthesis of triacylglycerol where as ABHD5 is a hydrolase and participates in the fatty acid oxidation process, yet inhibition of both enzymes similarly promotes prostate cancer cell death. Conclusion Inhibition of either DGAT1 or ABHD5 leads to prostate cancer cell death. Both DGAT1 and ABHD5 can be selectively targeted to block prostate cancer cell growth.
Collapse
Affiliation(s)
- Ranjana Mitra
- College of Medicine, Roseman University of Health Sciences, 10530 Discovery drive, Las Vegas, NV, 89135, USA.
| | - Thuc T Le
- College of Medicine, Roseman University of Health Sciences, 10530 Discovery drive, Las Vegas, NV, 89135, USA
| | - Priyatham Gorjala
- College of Medicine, Roseman University of Health Sciences, 10530 Discovery drive, Las Vegas, NV, 89135, USA
| | - Oscar B Goodman
- College of Medicine, Roseman University of Health Sciences, 10530 Discovery drive, Las Vegas, NV, 89135, USA. .,Comprehensive Cancer Centers of Nevada, 9280 W Sunset Road, Las Vegas, NV, 89148, USA.
| |
Collapse
|
6
|
Cernak T, Gesmundo NJ, Dykstra K, Yu Y, Wu Z, Shi ZC, Vachal P, Sperbeck D, He S, Murphy BA, Sonatore L, Williams S, Madeira M, Verras A, Reiter M, Lee CH, Cuff J, Sherer EC, Kuethe J, Goble S, Perrotto N, Pinto S, Shen DM, Nargund R, Balkovec J, DeVita RJ, Dreher SD. Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors. J Med Chem 2017; 60:3594-3605. [DOI: 10.1021/acs.jmedchem.6b01543] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Tim Cernak
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Nathan J. Gesmundo
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Kevin Dykstra
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Yang Yu
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhicai Wu
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhi-Cai Shi
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Petr Vachal
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Donald Sperbeck
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Shuwen He
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Beth Ann Murphy
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Lisa Sonatore
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Steven Williams
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Maria Madeira
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Andreas Verras
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Maud Reiter
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Claire Heechoon Lee
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - James Cuff
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Edward C. Sherer
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Jeffrey Kuethe
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Stephen Goble
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Nicholas Perrotto
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Shirly Pinto
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Dong-Ming Shen
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Ravi Nargund
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - James Balkovec
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Robert J. DeVita
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Spencer D. Dreher
- Department of Discovery Chemistry, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
7
|
Affiliation(s)
- Matthew C T Fyfe
- Topivert Limited, Imperial College Incubator, London, United Kingdom
| |
Collapse
|
8
|
Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes. Eur J Med Chem 2015. [DOI: 10.1016/j.ejmech.2015.06.043] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
He S, Hong Q, Lai Z, Yang DX, Ting PC, Kuethe JT, Cernak TA, Dykstra KD, Sperbeck DM, Wu Z, Yu Y, Yang GX, Jian T, Liu J, Guiadeen D, Krikorian AD, Sonatore LM, Wiltsie J, Liu J, Gorski JN, Chung CC, Gibson JT, Lisnock J, Xiao J, Wolff M, Tong SX, Madeira M, Karanam BV, Shen DM, Balkovec JM, Pinto S, Nargund RP, DeVita RJ. Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety. ACS Med Chem Lett 2014; 5:1082-7. [PMID: 25349648 DOI: 10.1021/ml5003426] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2014] [Accepted: 09/08/2014] [Indexed: 02/01/2023] Open
Abstract
We report the discovery of a novel series of DGAT1 inhibitors in the benzimidazole class with a piperdinyl-oxy-cyclohexanecarboxylic acid moiety. This novel series possesses significantly improved selectivity against the A2A receptor, no ACAT1 off-target activity at 10 μM, and higher aqueous solubility and free fraction in plasma as compared to the previously reported pyridyl-oxy-cyclohexanecarboxylic acid series. In particular, 5B was shown to possess an excellent selectivity profile by screening it against a panel of more than 100 biological targets. Compound 5B significantly reduces lipid excursion in LTT in mouse and rat, demonstrates DGAT1 mediated reduction of food intake and body weight in mice, is negative in a 3-strain Ames test, and appears to distribute preferentially in the liver and the intestine in mice. We believe this lead series possesses significant potential to identify optimized compounds for clinical development.
Collapse
Affiliation(s)
- Shuwen He
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Qingmei Hong
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Zhong Lai
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - David X. Yang
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Pauline C. Ting
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jeffrey T. Kuethe
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Timothy A. Cernak
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Kevin D. Dykstra
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Donald M. Sperbeck
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Zhicai Wu
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Yang Yu
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Ginger X. Yang
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Tianying Jian
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jian Liu
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Deodial Guiadeen
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Arto D. Krikorian
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Lisa M. Sonatore
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Judyann Wiltsie
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jinqi Liu
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Judith N. Gorski
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Christine C. Chung
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jack T. Gibson
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - JeanMarie Lisnock
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jianying Xiao
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Michael Wolff
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Sharon X. Tong
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Maria Madeira
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Bindhu V. Karanam
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Dong-Ming Shen
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - James M. Balkovec
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Shirly Pinto
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Ravi P. Nargund
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Robert J. DeVita
- Early Development and Discovery
Sciences, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
10
|
Lipunova GN, Nosova EV, Charushin VN. Fluorine-Containing Benzimidazoles and Their [a]- and [b]Heteroannelated Derivatives: Synthesis and Biological Activity (Review). Chem Heterocycl Compd (N Y) 2014. [DOI: 10.1007/s10593-014-1533-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|